Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology

被引：6

作者：

Alidousty, Christina ^{[1
]}

Baar, Till ^{[2
]}

Heydt, Carina ^{[1
]}

Wagener-Ryczek, Svenja ^{[1
]}

Kron, Anna ^{[3
,4
,5
]}

Wolf, Juergen ^{[3
,4
,5
]}

Buettner, Reinhard ^{[1
,3
,4
]}

Schultheis, Anne Maria ^{[1
]}

机构：

[1] Univ Hosp Cologne, Inst Pathol, Cologne, Germany

[2] Univ Cologne, Fac Med, Inst Med Stat & Computat Biol, Cologne, Germany

[3] Network Genom Med, Cologne, Germany

[4] Univ Hosp Cologne, Dept Internal Med 1, Lung Canc Grp Cologne, Cologne, Germany

[5] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

来源：

JOURNAL OF THORACIC DISEASE | 2019年 / 11卷

关键词：

Non-small cell lung cancer (NSCLC); anaplastic lymphoma kinase (ALK); ALK plus -adenocarcinoma; TP53; biomarker; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB RESISTANCE; PRACTICE GUIDELINES; TARGETED THERAPY; GROWTH-FACTOR; ALK; MUTATIONS; RECEPTOR; IDENTIFICATION; DIAGNOSIS;

D O I：

10.21037/jtd.2018.12.03

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

One distinct molecular subtype of non-small cell lung cancer (NSCLC) is defined by rearrangement of the anaplastic lymphoma kinase (ALK). The increasing knowledge over the last years has enabled the continuous improvement of ALK inhibitors; however, resistance in these patients remains a major concern. In this review, we summarize recent findings in ALK+-adenocarcinoma of the lung, highlighting the role of TP53 mutations in this specific cancer type and suggest new diagnostic strategies for the future, in order to improve patient's outcome.

引用

页码：S3 / S8

页数：6